Closing Thoughts on Managing Chronic Myeloid Leukemia http://bit.ly/22pxzJk
Jorge Cortes, MD: Very good. I think this has been a great discussion, and as you can see, we've reviewed a lot of the different data and I've learned a lot. And every time we discuss these things, I think we all learn a lot and that tells us that not everything about CML is well known. There's still things that are controversial. There's still a lot of things that we need to continue discussing and understand better by listening to each other. And I think that's the value of programs like this. So, just to conclude, I would like to ask each one of you to give me, very briefly, your final thoughts, a final message that you want to give to the physicians out there that are treating patients with CML. I'll start with you, Harry.
Harry Erba, MD, PhD: Well, you have three choices now. The second-generation drugs have shown a lower risk of progression with a manageable toxicity profile. I think the important point is whichever one you choose, you optimize adherence and reduce toxicities of any of them by close monitoring of patients. And it's very important to do not only hematologic monitoring, but PCR monitoring at baseline, at three months, and every three months afterward. Try to avoid rapid changes between drugs because of intolerances that could be managed or for a single PCR value that's a little bit out of range or out of whack to what it was before. Make sure you recheck it before you make any big decisions.
- See more at: http://www.onclive.c...h.qDMlOlkg.dpuf